The terminal phase may be crucial in the management of PE, as complement inhibitors, such as anti-C5 (73) or antagonists of C5a receptor, reverted the angiogenic imbalance, prevented growth restriction and hypertension, and rescued pregnancies in an animal model (74). The gene discussed is C5; the disease is hypertensive disorder.